Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Angiogenesis is crucial to tumour initiation, survival and metastasis. Vascular endothelial growth factor (VEGF) is one of the most important pro-angiogenic factors in cancer development. Bevacizumab (a humanised monoclonal antibody against VEGF) has a reasonable safety profile and proven efficacy in a phase III trial in advanced colorectal cancer. Efficacy of Bevacizumab also looks promising in non small cell lung cancer, renal cancer and a variety of other solid tumours. Questions still surround optimal dosing and the appropriate selection of patients who are most likely to benefit. Future trials will address these questions and provide further translational insights.

Original publication

DOI

10.1093/annonc/mdi208

Type

Journal article

Journal

Ann Oncol

Publication Date

07/2005

Volume

16

Pages

999 - 1004

Keywords

Angiogenesis Inhibitors, Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Bevacizumab, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Humans, Mice, Neoplasms, Vascular Endothelial Growth Factor A